Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Generic versus brand name: the other drug war

James McCormack and John T. Chmelicek
Canadian Family Physician October 2014, 60 (10) 911;
James McCormack
Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia in Vancouver.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John T. Chmelicek
Assistant Professor in the Department of Family Medicine at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Is there any benefit to prescribing brand-name medications rather than generic brands?

Bottom line

According to the best available evidence, generic medications are bioequivalent and produce similar clinical outcomes to brand-name medications.

Evidence

Bioequivalence1

  • Regulators require 90% CIs for the maximum peak concentration and total drug exposure over time, or area under the curve (AUC), to be within the limits of 0.80 to 1.25.

    • -This means the absolute differences in bioequivalence must be no more than about 5% to 7%.

  • Between 1996 and 2007, 2070 single-dose bioequivalence studies showed the average differences in maximum peak concentration and AUC were 4.35% and 3.56%, respectively.

  • Overall, 98% of studies showed the AUCs of generic and innovator products differed by less than 10%.

  • Generic and brand-name levothyroxine have been shown to be bioequivalent.2

Clinical outcomes (brand-name vs generic medications)

  • A systematic review (38 trials) of cardiovascular medications3 found the following:

    • -Clinical equivalence was shown in 35 of 38 trials including all β-blocker, antiplatelet, statin, angiotensin-converting enzyme inhibitor, α-blocker, class 1 antiarrhythmic agent, and warfarin trials; and most diuretic (10 of 11) and calcium channel blocker (5 of 7) trials.

    • -Differences in single outcomes were found in 3 trials.

      • —Brand-name furosemide produced more diuresis in a 1985 trial.

      • —For calcium channel blockers, 2 trials found differences in the PR interval on electrocardiography but no associated changes in heart rate or other clinical outcomes.

  • A systematic review of warfarin4 found the following:

    • -Five trials (higher level evidence) found no statistically significant difference in international normalized ratio or dosage changes required.

    • -Six observational studies (lower level evidence) showed inconsistent results at higher risk of bias.

Context

  • Of 43 editorials on generic medication issues, 23 (53%) expressed negative views about generic substitution,3 while only 8% of trials found any difference in any outcome.3

  • If there were important clinical differences between generic and brand-name medications, companies would do studies to prove brand-name superiority and prevent losing millions of dollars from generic substitution.

    • -In fact, one company tried to suppress data demonstrating equivalence of its product to related generics.5

Implementation

Generic and brand-name medications produce similar clinical outcomes. Nonetheless, differences in shape, colour, taste, and name can lead to patient, and sometimes clinician, confusion. These differences have been associated with nonpersistent use of medications.6 Also, generic medications can contain different fillers, and rarely some patients might not tolerate the medication for that reason. To prevent confusion, it is essential that we let patients know they might, over time, receive medications that look or sound different but contain the exact same medication. If they have any concerns they should always check with their pharmacist, physician, or health care provider.

Notes

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Davit BM,
    2. Nwakama PE,
    3. Buehler GJ,
    4. Conner DP,
    5. Haidar SH,
    6. Patel DT,
    7. et al
    . Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacotherapy 2009;43(10):1583-97. Epub 2009 Sep 23.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Dong BJ,
    2. Hauck WW,
    3. Gambertoglio JG,
    4. Gee L,
    5. White JR,
    6. Bubp JL,
    7. et al
    . Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997;277(15):1205-13.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kesselheim AS,
    2. Misono AS,
    3. Lee JL,
    4. Stedman MR,
    5. Brookhart MA,
    6. Choudhry NK,
    7. et al
    . Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300(21):2514-26.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Dentali F,
    2. Donadini MP,
    3. Clark N,
    4. Crowther MA,
    5. Garcia D,
    6. Hylek E,
    7. et al
    . Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy 2011;31(4):386-93.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Worst Pills, Best Pills.
    Myths and facts about generic drugs. Public Citizen’s Health Research Group; 2014. Available from: www.worstpills.org/public/page.cfm?op_id=47. Accessed 2014 Jun 10.
  6. 6.↵
    1. Kesselheim AS,
    2. Bykov K,
    3. Avorn J,
    4. Tong A,
    5. Doherty M,
    6. Choudhry NK
    . Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case–control studies. Ann Intern Med 2014;161(2):96-103.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 60 (10)
Canadian Family Physician
Vol. 60, Issue 10
1 Oct 2014
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Generic versus brand name: the other drug war
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Generic versus brand name: the other drug war
James McCormack, John T. Chmelicek
Canadian Family Physician Oct 2014, 60 (10) 911;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Generic versus brand name: the other drug war
James McCormack, John T. Chmelicek
Canadian Family Physician Oct 2014, 60 (10) 911;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Tools for Practice

  • Topical combination products for facial acne
  • Budesonide bests COVID-19
  • Exercise for peripheral artery disease
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire